NovoCure Ltd NVCR
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of NovoCure Ltd shares you hold and we'll calculate your dividend payments:
Sign up for NovoCure Ltd and we'll email you the dividend information when they declare.
Add NovoCure Ltd to receive free notifications when they declare their dividends.
Your account is set up to receive NovoCure Ltd notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no NovoCure Ltd dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0c | — |
| 2007 | 0.0c | 0% |
| 2008 | 0.0c | 0% |
| 2009 | 0.0c | 0% |
| 2010 | 0.0c | 0% |
| 2011 | 0.0c | 0% |
| 2012 | 0.0c | 0% |
| 2013 | 0.0c | 0% |
| 2014 | 0.0c | 0% |
| 2015 | 0.0c | 0% |
| 2016 | 0.0c | 0% |
| 2017 | 0.0c | 0% |
| 2018 | 0.0c | 0% |
| 2019 | 0.0c | 0% |
| 2020 | 0.0c | 0% |
| 2021 | 0.0c | 0% |
| 2022 | 0.0c | 0% |
| 2023 | 0.0c | 0% |
| 2024 | Sign Up Required | |
NovoCure Ltd Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 22 November 2023
- 52 Week Low
- 0.0% on 22 November 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About NovoCure Ltd
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United States
- Share Price
- $16.86 (yesterday's closing price)
- Shares in Issue
- 108 million
- Market Cap
- $1.8bn
- 0
- Market Indices
- none
